Understanding oncogenesis

How normal cells turn into liver cancer cells

Researchers at the University of Helsinki could show for the first time that normal human fibroblast cells can be converted to specific cancer cells using only factors that are commonly detected in actual human patients.

Photo
3D printed liver model

Previous studies have achieved this only by using powerful viral factors that are not common in human cancers. Since many human cancer types still lack specific diagnostic markers or effective targeted therapies, these mechanistic insights are important for developing novel diagnostic and treatment options.

The research group of Professor Jussi Taipale that belongs to the Academy of Finland’s Center of Excellence in Tumor Genetics Research, developed a novel cellular transformation assay for studying the mutations that cause human cancer on a molecular level. Using this novel assay, researchers were able to identify a minimal set of defined factors that can convert a normal human fibroblast cell to a liver cancer cell. They also discovered that cellular lineage and differentiation stage are critical factors that determine cell’s response to oncogenic mutations. This provides a mechanistic proof-of-principle for understanding why certain mutations cause cancer in particular tissues. The study led by Dr. Biswajyoti Sahu was recently published in Oncogene. “This is a first-of-its-kind study that introduced a novel approach to systematically investigate molecular determinants causing human cancers” says Dr. Sahu.

This study can have a major impact on better understanding of tumorigenic mechanisms in the future

Jussi Taipale

The innovative feature of the novel cellular transformation assay is to utilize cellular transdifferentiation, in which human fibroblast cells are converted to a different cell type using defined transcription factors, and to expose the cells to oncogenic factors during this transdifferentiation process. “Since previous cancer genome sequencing studies have reported mutations in over 250 genes in different human tumor types, novel methods for studying their effects on tumorigenesis are highly warranted”, Dr. Sahu points out.

Cancer can arise from various different human tissues. Although the common feature of all cancers is malignant growth caused by mutations in genes regulating critical cellular processes such as proliferation and apoptosis, same mutations do not cause cancer in all tissues. However, why a particular mutation causes cancer in some tissues but not in others is not well understood.

In this study, the authors identified the set of factors that can make normal cells to liver cancer cells by systematically studying different mutations that have previously been reported in human liver tumors. ”Our focus was on liver cancer, but importantly, a similar approach can be used for studying various other human cancer types. Thus, this study can have a major impact on better understanding of tumorigenic mechanisms in the future”, says Professor Taipale.


Source: University of Helsinki

07.09.2021

Read all latest stories

Related articles

Photo

Oncology early detection tool

Blood test for 50+ types of cancer promising for screening

Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher…

Photo

Enhancing T cell response

New targets for cancer vaccines identified

Over the past decade, scientists have been exploring vaccination as a way to help fight cancer. These experimental cancer vaccines are designed to stimulate the body’s own immune system to destroy…

Photo

Software solution

Using AI to match cancer patients to early phase clinical trials

Cancer informatics and digital pathology provider Inspirata announced that King’s Health Partners ECMC and Guy’s and St Thomas’ NHS Foundation Trust will pilot its Trial Navigator software as…

Related products

Canon - Aquilion Exceed LB

Oncology CT

Canon - Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Siemens Healthineers – Somatom go.Open Pro

Oncology CT

Siemens Healthineers – Somatom go.Open Pro

Siemens Healthineers
Siemens Healthineers – Somatom go.Sim

Oncology CT

Siemens Healthineers – Somatom go.Sim

Siemens Healthineers
Subscribe to Newsletter